IDEAYA Biosciences (IDYA) news
Recent news
Ideaya Biosciences, - To initiate phase 3 trial for IDE849 by year-end 2026 in ES-SCLC
AInvest Wire · 9h agoIdeaya Biosciences announces clinical pact with Genentech
AInvest Wire · Aug 19, 2026Ideaya Biosciences - to supply Ide892 for clinical trial
IDEAYA Biosciences (NASDAQ: IDYA) has announced the initiation of Part 2 monotherapy expansion in its Phase 1/2 clinical trial of IDE892, a potential best-in-class methylthioadenosine (MTA)-cooperative inhibitor of PRMT5, for MTAP-deleted solid tumors , including non-small cell lung cancer (NSCLC)…
AInvest Wire · Aug 19, 2026Ideaya Biosciences cash runway guidance into '30 is unchanged
AInvest Wire · Aug 4, 2026Ideaya Biosciences announces inducement grants under Nasdaq listing Rule 5635(c)(4)
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) has made multiple equity award grants under its 2023 Employment Inducement Incentive Award Plan to newly hired employees in 2026, in compliance with Nasdaq Listing Rule 5635(c)(4). On April 30, 2026, the company granted non-qualified stock options to purchase…
AInvest Wire · Jun 26, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.